Diffusion Pharmaceuticals to Present at JMP Securities Life Sciences Conference

CHARLOTTESVILLE, Va., June 01, 2016 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management will be presenting at the JMP Securities Life Sciences Conference to be held June 21- 22, 2016 in New York, NY.

David Kalergis, Chairman and Chief Executive Officer of Diffusion, is scheduled to present on Tuesday, June 21, 2016 at 2:30 PM ET.

The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the Investor Relations section of Diffusion's website, www.diffusionpharma.com. 

About Diffusion PharmaceuticalsDiffusion Pharmaceuticals is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments including radiation therapy and chemotherapy.  Diffusion is developing its lead drug, trans sodium crocetinate (TSC), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments.  TSC targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects.

A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (GBM).  This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care.  The U.S. Food and Drug Administration has agreed upon the design of a Phase 3 trial in newly diagnosed GBM.  Additional planned studies, subject to receipt of necessary financing, include the Phase 2 trial in pancreatic cancer and a study in brain metastases. Due to its novel mechanism of action, TSC has safely re-oxygenated a range of tumor types in our preclinical and clinical studies. The Company believes its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve standard-of-care treatments of other life-threatening cancers. We also believe that TSC has potential application in other indications involving hypoxia, such as stroke and neurodegenerative diseases.

Diffusion Pharmaceuticals Contacts

David Kalergis
Chief Executive Officer
Diffusion Pharmaceuticals Inc.
(434) 220-0718
[email protected]

Stephanie Carrington
ICR Inc.
(646) 277-1282
[email protected]

Source: Diffusion Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
• Dimensional Fund Advisors Ltd. : Form 8.3 - Irish Continental Group Plc - Ordinary Shares
• Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update